Indoramin: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 17, 2026🚩 Report this page

Indoramin

Alpha-Adrenoreceptor Antagonists

GB MHRA

Drug class: Alpha-Adrenoreceptor Antagonists
Availability: See label
Markets covered: 1
Products on record: 4

Overview

Indoramin is an active pharmaceutical ingredient in the Alpha-Adrenoreceptor Antagonists group (C02CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	4	April 17, 2026

GBUnited Kingdom· MHRA

4 products

Uses

GBOfficial regulatory label· revised July 11, 2025[1]

Conditions for which alpha blockade is indicated. Management of urinary outflow obstruction due to benign prostatic hyperplasia.

How to take

Sources & citations

[1]MHRA (UK) · PL177360089 · revised July 11, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised July 11, 2025[1]

Drowsiness or sedation can occur on starting treatment with indoramin, and also if dosage is increased too rapidly. Less commonly, dry mouth, nasal congestion, weight gain, dizziness, failure of ejaculation, depression, fatigue, headache and hypotension (including postural hypotension) with or without syncope may occur.
Rarely, Parkinson's disease could be exacerbated. Rarely, hypersensitivity reactions including rash and pruritus may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised July 11, 2025[1]

Incipient cardiac failure should be controlled before treatment with indoramin. Caution should be observed in prescribing indoramin for patients with hepatic or renal insufficiency. A few cases of extrapyramidal disorders have been reported in patients treated with indoramin.
Caution should be observed in prescribing indoramin in patients with Parkinson's disease. In animals and in the one reported case of overdose in humans, convulsions have occurred. Due consideration should be given, and great caution exercised in the use of indoramin in patients with epilepsy.
The 'Intraoperative Floppy Iris Syndrome (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded.
As IFIS may lead to increased procedural complications during the cataract operation current or part use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery. Caution should be observed in prescribing indoramin for patients with a history of depression.
Clearance of indoramin may be affected in the elderly. A reduced dose, and/or reduced frequency of dosing may be sufficient in some elderly patients. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations